Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2026-01-09 @ 2:03 AM
Study NCT ID:
NCT00478634
Status:
COMPLETED
Last Update Posted:
2012-11-02
First Post:
2007-05-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-05
Start Date Type:
None
Primary Completion Date:
2009-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-09
Completion Date Type:
ACTUAL
First Submit Date:
2007-05-24
First Submit QC Date:
None
Study First Post Date:
2007-05-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-11-01
Last Update Post Date:
2012-11-02
Last Update Post Date Type:
ESTIMATED